Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration

Elman Michael J.; Brown David M.; Kaiser Peter K.; Slakter Jason S.

首页> 外文期刊>Investigative ophthalmology & visual science >Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration

【24h】

Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration

机译：与Ranibizimab双药草的治疗幼鱼乳蛋白单疗法与Ranibizimab与ranibizimab与Ranibizimab单疗法相比，与Ranibizimab的单一治疗与Ranibizimab双胍溶解的临床研究与Ranibizimab Ophthalmic溶液相比，与Ranibizimab的治疗中的治疗中的幼苗单一治疗相比，临床研究与Ranibizimizumab相比。退化

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Investigative ophthalmology & visual science》 |2018年第9期|共2页
作者
Elman Michael J.; Brown David M.; Kaiser Peter K.; Slakter Jason S.;
展开▼
作者单位

Elman Retina Grp PA Baltimore MD USA;

Retina Consultants Houston Houston TX USA;

Cleveland Clin Cleveland OH 44106 USA;

Ohr Pharmaceut Inc New York NY USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular DegenerationClinical Study of Squalamine Lactate Ophthalmic Solution 0.2% in Combination with Ranibizumab Compared to Ranibizimab Monotherapy in Treatment Naive Neovascular Age-Related Macular Degeneration [J] . Elman Michael J., Brown David M., Kaiser Peter K., Investigative ophthalmology & visual science . 2018,第9期

机译：与Ranibizimab双药草的治疗幼鱼乳蛋白单疗法与Ranibizimab与ranibizimab与Ranibizimab单疗法相比，与Ranibizimab的单一治疗与Ranibizimab双胍溶解的临床研究与Ranibizimab Ophthalmic溶液相比，与Ranibizimab的治疗中的治疗中的幼苗单一治疗相比，临床研究与Ranibizimizumab相比。退化
2. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [J] . Vallance JH, Johnson B, Majid MA, Eye . 2010,第10期

机译：比较光动力疗法与玻璃体内雷珠单抗与玻璃体内雷珠单抗单药联合治疗新血管性年龄相关性黄斑变性的随机前瞻性双盲探索性研究。
3. LUCEDEX: A prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration [J] . RanchodT.M., RayS.K., DanielsS.A., Retina . 2013,第8期

机译：LUCEDEX：一项前瞻性研究，比较了兰尼单抗联合地塞米松联合治疗与兰尼单抗单药治疗新血管性年龄相关性黄斑变性
4. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration [O] . Patrick D Williams, David Callanan, Wayne Solley, 2012

机译：前瞻性先导研究比较玻璃体内雷珠单抗和半定量光动力疗法与雷珠单抗单药联合治疗新血管性年龄相关性黄斑变性的疗效
5. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration [O] . J H Vallance, B Johnson, M A Majid, 2010

机译：随机预期双掩盖探索性研究比较组合光动力处理和玻璃体内ranibizumab与玻璃体内Ranibizumab单一治疗治疗新生血管年龄相关性黄斑变性

著录项

相似文献

相关主题

期刊订阅